المؤلفون: Schellens, J. H. M., Dombernowsky, P., Cassidy, J., Epelbaum, R., Dirix, L., Cox, E. H., Wanders, J., Calabresi, F., Paridaens, R., Monfardini, S., Wolff, J., Loos, W. J., Verweij, J., Pavlidis, Nicholas, Hanauske, A. R.

المساهمون: EORTC Early Clinical Studies Grp, Medical Oncology, Erasmus School of Social and Behavioural Sciences, Pavlidis, Nicholas [0000-0002-2195-9961]

المصدر: Anti-cancer drugs: an international journal on anti-cancer agents
Anti-Cancer Drugs, 12, 583-590. Lippincott Williams & Wilkins
Anti-Cancer Drugs

مصطلحات موضوعية: Male, Cancer Research, Indoles, Indoles/*pharmacokinetics, Unclassified drug, Alkylating agent, Drug exposure, Aziridines, Population Dynamics, Pharmacology, Controlled clinical trial, Neoplasms, Antineoplastic agents, 80 and over, Sampling studies, Medicine, Neoplasms/drug therapy/*metabolism, Pharmacology (medical), Prospective Studies, Middle aged, Drug safety, Prospective cohort study, Antineoplastic Agents/*pharmacokinetics, Priority journal, 5 (1 aziridinyl) 3 hydroxymethyl 2 (3 hydroxy 1 propenyl) 1 methyl 4, media_common, Aged, 80 and over, Area under the curve, Population analysis, education.field_of_study, Eo9, Pharmacology. Therapy, Cytotoxic agent, Middle Aged, Phase ii, Algorithm, Clinical trial, Indolequinones, Oncology, Area Under Curve, Toxicity, Drug clearance, Female, Cancer chemotherapy, Human, Adult, Drug, Indoloquinone, Population dynamics, Metabolic Clearance Rate, media_common.quotation_subject, Population, Drug response, Antineoplastic Agents, Major clinical study, Article, Sampling Studies, Bayesian algorithm, Aziridines/*pharmacokinetics, Pharmacokinetics, Humans, Phase 2 clinical trial, Prospective study, Area under curve, education, Aged, Quinone derivative, business.industry, 7 indoledione, Phase 1 clinical trial, Pharmacodynamics, Human medicine, Metabolic clearance rate, business, Controlled study, Prospective studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dafb269bf9a88af154380686eafb058bTest
https://doi.org/10.1097/00001813-200108000-00004Test

المؤلفون: Dirix, L. Y., Tonnesen, F., Cassidy, J., Epelbaum, R., Huinink, W. W. Ten Bokkel, Pavlidis, Nicholas, Sorio, R., Gamucci, T., Wolff, I., Velde, A. Te, Lan, J., Verweij, J.

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961]

المصدر: European journal of cancer
European Journal of Cancer Part A

مصطلحات موضوعية: Male, Cancer Research, Indoles, Pancreatic disease, Colorectal cancer, medicine.medical_treatment, Aziridines, Phases of clinical research, Digestive System Neoplasms, Gastroenterology, Antineoplastic Agents/*adverse effects/therapeutic use, Breast cancer, Pancreatic Neoplasms/drug therapy, Antineoplastic agents, 80 and over, Indoles/*adverse effects/therapeutic use, Middle aged, Pancreas cancer, Priority journal, 5 (1 aziridinyl) 3 hydroxymethyl 2 (3 hydroxy 1 propenyl) 1 methyl 4, Aged, 80 and over, Eo9, Breast Neoplasms/*drug therapy, Colorectal Neoplasms/drug therapy, Nausea, Middle Aged, Multicenter study, Digestive System Neoplasms/*drug therapy, Clinical trial, Indolequinones, Proteinuria, medicine.anatomical_structure, Oncology, Female, Colorectal Neoplasms, Pancreas, Human, Adult, medicine.medical_specialty, Pancreatic neoplasms, Vomiting, Stomach cancer, Stomach neoplasms, Aziridines/*adverse effects/therapeutic use, Antineoplastic Agents, Breast Neoplasms, Major clinical study, Follow-up studies, Article, Colorectal neoplasms, Proteinuria/chemically induced, Stomach Neoplasms, Pancreatic cancer, Internal medicine, medicine, Humans, Phase 2 clinical trial, Aged, Antineoplastic activity, Chemotherapy, business.industry, 7 indoledione, Phase ii study, Cancer, medicine.disease, Pancreatic Neoplasms, Digestive system neoplasms, Renal toxicity, Stomach Neoplasms/drug therapy, Intravenous drug administration, Human medicine, Breast neoplasms, Gastric cancer, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63e22d5b3f7daefd9445b39d685d20fTest
https://doi.org/10.1016/0959-8049Test(96)00226-2

المؤلفون: Pavlidis, Nicholas, Hanauske, A. R., Gamucci, T., Smyth, J. F., Lehnert, M., Velde, A. Te, Lan, J., Verweij, J.

المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961]

المصدر: Annals of Oncology

مصطلحات موضوعية: Male, Aziridines/adverse effects/therapeutic use, Indoles, Lung Neoplasms, Nsclc, Pleural effusion, medicine.medical_treatment, Aziridines, Phases of clinical research, Gastroenterology, law.invention, Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology, Randomized controlled trial, law, Carcinoma, Non-Small-Cell Lung, Controlled clinical trial, Nephrotoxicity, Priority journal, 5 (1 aziridinyl) 3 hydroxymethyl 2 (3 hydroxy 1 propenyl) 1 methyl 4, Aged, 80 and over, Eo9, Antineoplastic Agents/adverse effects/therapeutic use, Nausea, Hematology, Middle Aged, Multicenter study, Survival Rate, Clinical trial, Indolequinones, Treatment Outcome, Antineoplastic agent, Lung non small cell cancer, Oncology, Injections, Intravenous, Vomiting, Female, medicine.symptom, Human, Adult, medicine.medical_specialty, Randomization, Indoloquinone, Indoles/adverse effects/therapeutic use, Clinical article, Antineoplastic Agents, Drug Administration Schedule, Article, Indoloquinoline derivative, Lung Neoplasms/*drug therapy/pathology, Internal medicine, medicine, Humans, Lung cancer, Aged, Chemotherapy, Dose-Response Relationship, Drug, Toxicity, business.industry, 7 indoledione, medicine.disease, Surgery, Intravenous drug administration, business, Controlled study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c98c1ad912115bcfe2ddf13840f09bTest
https://doi.org/10.1093/oxfordjournals.annonc.a010645Test